Hostname: page-component-8448b6f56d-t5pn6 Total loading time: 0 Render date: 2024-04-16T15:39:54.976Z Has data issue: false hasContentIssue false
  • English
  • Français

1689 – Ginkgo Biloba Extract Egb 761 In Mild Cognitive Impairment With Neuropsychiatric Symptoms: a Randomized Placebo-controlled Trial

Published online by Cambridge University Press:  15 April 2020

U.W. Preuss ,
N. Bachinskaya ,
R. Kaschel ,
J.W. Wong ,
R. Hoerr  and
S.I. Gavrilova
U.W. Preuss
Affiliation:
Department of Psychiatry, Psychotherapy and Psychosomatics, Kreiskrankenhaus Prignitz, Perleberg, Germany
N. Bachinskaya
Affiliation:
Institute of Gerontology, Academy of Medical Sciences, Kiev, Ukraine, Germany
R. Kaschel
Affiliation:
Department of Psychology, University of Osnabrueck, Osnabrueck, Germany
J.W. Wong
Affiliation:
Department of Psychiatry, Psychotherapy and Psychosomatics, Kreiskrankenhaus Prignitz, Perleberg, Germany
R. Hoerr
Affiliation:
Clinical Research Department, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany
S.I. Gavrilova
Affiliation:
Mental Health Research Center, Russian Academy of Medical Sciences, Moscow, Russia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Ginkgo biloba extract EGb 761® improved neuropsychiatric symptoms (NPS) in patients with dementia in a series of trials.

Objectives/aims

To explore the effects of EGb 761® on NPS in patients with mild cognitive impairment (MCI).

Methods

A randomized, placebo-controlled, double-blind, 24-week, multi-center trial was conducted, including 160 patients with MCI who scored at least 6 on the 12-item Neuropsychiatric Inventory (NPI). Effects on NPS were assessed using the NPI, the state sub-score of the State-Trait Anxiety Inventory (STAI-X1) and the Geriatric Depression Scale (GDS). Further outcome measures were the Trail-Making Test (TMT, Forms A and B) and global ratings of change. Descriptive statistical analyses followed the intention-to-treat principle.

Results

The NPI composite score decreased by 7.0 ± 4.5 (mean, standard deviation) points in the EGb 761®-treated group and by 5.5 ± 5.2 points in the placebo group (p = 0.001). Improvement by at least 4 points was found in 78.8% of patients treated with EGb 761® and in 55.7% of those receiving placebo (p = 0.002). Significant superiority of EGb 761® over placebo was also found for the STAI-X1 score, the informants' global impression of change and both TMT scores. There were statistical trends favoring EGb 761® in the GDS and the patients' global impression of change. Adverse events were reported by 37 patients taking EGb 761® and 36 patients receiving placebo; there were no serious adverse events.

Conclusion

EGb 761® improved NPS and cognitive performance in patients with MCI. The drug was safe and well tolerated.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E965
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.